The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 23, 2021
Filed:
Apr. 24, 2019
Applicant:
Immunomedics, Inc., Morris Plains, NJ (US);
Inventors:
Chien-Hsing Chang, Downingtown, PA (US);
David M. Goldenberg, Mendham, NJ (US);
Assignee:
Immunomedics, Inc., Morris Plains, NJ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); A61K 45/06 (2006.01); A61K 39/395 (2006.01); A61K 51/10 (2006.01); C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61K 31/4535 (2006.01); A61K 31/473 (2006.01); A61K 31/4745 (2006.01); A61K 31/4985 (2006.01); A61K 41/00 (2020.01);
U.S. Cl.
CPC ...
C07K 16/3061 (2013.01); A61K 31/4535 (2013.01); A61K 31/473 (2013.01); A61K 31/4745 (2013.01); A61K 31/4985 (2013.01); A61K 39/3955 (2013.01); A61K 41/0038 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 47/6851 (2017.08); A61K 47/6889 (2017.08); A61K 51/1057 (2013.01); C07K 16/2887 (2013.01); C07K 16/30 (2013.01); C07K 16/303 (2013.01); C07K 16/3007 (2013.01); C07K 16/3015 (2013.01); C07K 16/3023 (2013.01); C07K 16/3038 (2013.01); C07K 16/3046 (2013.01); C07K 16/3053 (2013.01); C07K 16/3069 (2013.01); C07K 16/3092 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/77 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01);
Abstract
The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.